Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines

Journal of Hepatology

Volumn 56, Issue 4, 2012, Pages 886-892

  Takayasu, Kenichi ^a   Arii, Shigeki ^b   Kudo, Masatoshi ^c   Ichida, Takafumi ^d   Matsui, Osamu ^e   Izumi, Namiki ^f   Matsuyama, Yutaka ^g   Sakamoto, Michiie ^h   Nakashima, Osamu ⁱ   Ku, Yonson ^j   Kokudo, Norihiro ^k   Makuuchi, Masatoshi ^l  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^e KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^f MUSASHINO RED CROSS HOSPITAL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KURUME UNIVERSITY HOSPITAL   (Japan)

^j KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l JAPANESE RED CROSS MEDICAL CENTER   (Japan)

more..

Author keywords

Hepatocellular carcinoma (HCC); Japanese guidelines; Prognostic factor; Transcatheter arterial chemoembolization (TACE); Validation of treatment algorithm

Indexed keywords

ALPHA FETOPROTEIN; GELATIN SPONGE; IODINATED POPPYSEED OIL; SHU 508; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; JAPAN; LIVER ANGIOGRAPHY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ALGORITHMS; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; FEMALE; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL RATE;

EID: 84858702846     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.10.021     Document Type: Article

References (14)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. J. Bruix, and J.M. Llovet Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 35 2002 519 524 (Pubitemid 34183954)
3. I. Ikai, M. Kudo, S. Arii, M. Omata, M. Kojiro, and M. Sakamoto Report of the 18th follow up survey of primary liver cancer in Japan Hepatol Res 40 2010 1043 1059
4. O. Matsui, M. Kadoya, J. Yoshikawa, T. Gabata, K. Arai, and H. Demachi Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization Radiology 188 1993 79 83 (Pubitemid 23183103)
5. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430 (Pubitemid 32844200)
6. M. Makuuchi, N. Kokudo, S. Arii, S. Futagawa, S. Kaneko, and S. Kawasaki Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan Hepatol Res 38 2008 37 51 (Pubitemid 350182575)
7. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 2nd English ed. Tokyo, Japan: Kanehara & Co., Ltd.; 2003.
8. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, and F. Bozzetti Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699 (Pubitemid 26079803)
9. K. Takayasu, S. Arii, I. Ikai, M. Omata, K. Okita, and T. Ichida Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients Gastroenterology 131 2006 461 469 (Pubitemid 44142456)
10. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
11. T. Takayama Hepatocellular carcinoma P.A. Clavien, Malignant liver tumors: current and emerging therapies 3rd ed. 2010 Wiley-Blackwell London 317 323
12. A. Sergio, C. Cristofori, R. Cardin, G. Pivetta, R. Ragazzi, and A. Baldan Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness Am J Gastroenterol 103 2008 914 921 (Pubitemid 351506379)
13. Lencioni R, Zou J, Leberre M, Meinhardt G, Voliotis D, Bruix J, et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). ASCO Meeting Abstracts 2010;28:TPS178.
14. L. Marelli, R. Stigliano, C. Triantos, M. Senzolo, E. Cholongitas, and N. Davies Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 30 2007 6 25 (Pubitemid 44900485)